Alexander Tamalunas
Overview
Explore the profile of Alexander Tamalunas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keller P, Hu S, Berger L, Nicola P, Schierholz F, Tamalunas A, et al.
Sci Rep
. 2025 Feb;
15(1):4985.
PMID: 39929919
Prostate smooth muscle contraction is central in treatment of voiding symptoms in benign prostatic hyperplasia (BPH). Tissues from transurethral resection of the prostate (TURP) and radical prostatectomy (RP) for prostate...
2.
Tamalunas A, Paktiaval R, Lenau P, Stadelmeier L, Buchner A, Kolben T, et al.
Patient Prefer Adherence
. 2024 Dec;
18:2507-2518.
PMID: 39678359
Purpose: Lower urinary tract symptoms (LUTS) consist of voiding and storage symptoms. While the therapeutic efficacy of current LUTS medications is limited, and with more than 20% of patients suffering...
3.
Ehmann L, Sultova V, Henkel L, Hohn H, Tamalunas A, Tremmel E, et al.
Arch Gynecol Obstet
. 2024 Nov;
310(6):3173-3181.
PMID: 39611957
Purpose: The purpose of this study was to analyse the factors that influence patients` choice of obstetric and gynaecological medical centre. Methods: Patients attending the gynaecological and obstetric outpatient department...
4.
Hennenberg M, Hu S, Tamalunas A, Stief C
Eur Urol Open Sci
. 2024 Nov;
70:154-157.
PMID: 39554302
Background And Objective: Genetic predisposition is a factor in 40-70% of cases of benign prostatic hyperplasia (BPH) and voiding symptoms. However, informal reviews summarizing genes and variants imparting genetic disposition...
5.
Huang R, Yu Q, Tamalunas A, Stief C, Hennenberg M
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000575
The β-adrenoceptor agonist mirabegron is available for the treatment of storage symptoms of overactive bladder, including frequency, urgency, and incontinence. The off-target effects of mirabegron include binding to α-adrenoceptors, which...
6.
Tamalunas A, Wendt A, Springer F, Vigodski V, Trieb M, Eitelberger N, et al.
Biomed Pharmacother
. 2024 Jul;
177:117066.
PMID: 38981242
Background: The immunomodulatory imide drugs (IMiDs) thalidomide, lenalidomide and pomalidomide may exhibit therapeutic efficacy in the prostate. In lower urinary tract symptoms (LUTS), voiding and storage disorders may arise from...
7.
Rodler S, Aydogdu C, Brinkmann I, Berg E, Kopliku R, Gotz M, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927951
Immune checkpoint inhibitor (ICI) therapies have been established as the standard-of-care in various uro-oncological cancers. Immune-related adverse events (irAEs) are frequent, but their degree rarely leads to the discontinuation of...
8.
Hu S, Muderrisoglu A, Ciotkowska A, Kale O, Keller P, Schott M, et al.
Pharmacol Rep
. 2024 Jun;
76(4):807-822.
PMID: 38858312
Background: Apart from antagonizing ß-adrenoceptors, carvedilol antagonizes vascular α-adrenoceptors and activates G protein-independent signaling. Even though it is a commonly used antihypertensive and α-adrenoceptors are essential for the treatment of...
9.
Tamalunas A, Keller P, Gotz M, Atzler M, Kidess M, Stadelmeier L, et al.
MMW Fortschr Med
. 2024 May;
166(8):40-43.
PMID: 38693388
No abstract available.
10.
Kidess M, Keller P, Tamalunas A, Askari-Motlagh D, Atzler M, Karatas D, et al.
MMW Fortschr Med
. 2024 May;
166(8):36-39.
PMID: 38693387
No abstract available.